This is a New York Times news story, not a scientific paper - so I'm not sure if this the right place to post this. A Cancer Trial’s Unexpected Result: Remission in Every Patient https://www.nytimes.com/2022/06/05/health/rectal-cancer-checkpoint-inhibitor.html At Memorial Sloan Kettering Cancer Center, 18 of 18 patients with rectal cancer caused by "a deficiency in mismatch repair" had (apparently total) remissions following treatment with a drug called "dostarlimab." It was a small trial with no control group, but the results have been called "unheard-of." Link to the paper in The New England Journal of Medicine here: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer [ The paper refers to success in 12 of 12 patients, so I assume that six more patients had equivalent results following the paper's submission. ] [ ETA: This is not a treatment for all types of rectal cancer. The type of cancer treated in this study only represents about 5% to 10% of all rectal cancers. ]
